Clinical Trial Update: A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) [Phase 1]

View source ↗

Summary

Phase 1 study of belzutifan as monotherapy and in combination with lenvatinib, with or without pembrolizumab, in Chinese participants with advanced renal cell c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)
• Welireg (belzutifan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Renal Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING